Ascorbic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ascorbic Acid: From Vitamin C Deficiency to Non-syndromic Esophageal Malformation
One-Sentence Summary
Ascorbic acid (vitamin C) is an essential vitamin and antioxidant, and its injectable forms are marketed in the US. The evidence pack does not list an original indication, so “vitamin C deficiency” is assumed here. The TxGNN model predicts it may be useful for non-syndromic esophageal malformation, but there are 0 clinical trials and 0 publications behind this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the evidence pack (label text is empty for all listed products) |
| Predicted New Indication | Non-syndromic esophageal malformation |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Ascorbic acid is known as an antioxidant and as a cofactor for collagen-forming enzymes, but the pack does not document this, and it does not explain the predicted indication.
The prediction is not mechanistically supported. Non-syndromic esophageal malformation is a congenital structural defect of the esophagus. An antioxidant or cofactor vitamin is not expected to correct such a defect. The 99.96% score is a model output only, and no trial or publication supports it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M001 | Super vitamin C serum | Liquid | Not listed |
| ANDA217131 | Ascorbic Acid (Fresenius Kabi USA) | Injection | Not listed |
| No number recorded | Vitamin C 10 % (Puretek) | Liquid | Not listed |
| No number recorded | Vitamin C 15 % (Puretek) | Liquid | Not listed |
| NDA209112 | Ascor (McGuff Pharmaceuticals) | Injection | Not listed |
The 20 licenses cover oral, injectable, topical and other forms.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature, and there is no plausible mechanism by which ascorbic acid would treat a congenital esophageal malformation. It should not advance beyond model screening.
To proceed, the following is needed:
- Package insert warnings and contraindications. This is currently a blocking gap for safety screening.
- Mechanism of action data, for example from DrugBank.
- Reconciliation of the approved indications, since the label text is empty for every product listed.
- Review of the other candidates in the same pack. “Vitamin deficiency disorder” (the only candidate at stage S2, marked “Research Question”) is probably an established use rather than true repurposing. “Esophageal disease” has mixed to negative signals, including rat data showing enhanced carcinogenesis and reports of pill-induced esophagitis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.